BWX Technologies has entered into a definitive agreement to sell its medical-isotope and radiopharmaceutical business to Nordic Capital in a transaction valued at up to US$800 million.

The transaction covers BWXT Medical and the stable medical-isotope business operated through Kinectrics. BWXT will retain a meaningful minority ownership position in the new company and continue providing specialised isotope and radiochemical expertise under the agreement.

The sale remains subject to customary regulatory approvals and other closing conditions. BWXT expects the transaction to close by the end of 2026.

The agreement represents a major investment in the expanding radiopharmaceutical industry. It also illustrates the growing commercial value attached to the complex infrastructure required to produce isotopes for diagnostic imaging and targeted cancer treatment.

For African countries, however, the central question is not simply whether global investment in nuclear medicine is increasing.

It is whether that investment will translate into more reliable, affordable and geographically accessible treatment for African patients.

A Strategic Divestment, Not an Exit From Nuclear Medicine

BWXT said the transaction would allow it to concentrate management attention and capital on its core nuclear national-security and commercial nuclear-power businesses.

The company nevertheless remains optimistic about the long-term prospects of radiopharmaceuticals. Its retained minority ownership and continuing technical-support role indicate that it intends to participate in the future growth of the business rather than withdraw completely from the sector.

BWXT President and Chief Executive Officer Rex Geveden said the medical business had approximately tripled its revenue, improved profitability and expanded its product portfolio since BWXT acquired it in 2018.

Under Nordic Capital’s ownership, the business is expected to pursue further expansion in the development, manufacture and delivery of products for diagnostic imaging and radiotherapeutic treatment.

Nordic Capital manages approximately €39 billion in assets and identifies healthcare as one of its core investment sectors. The investor said it saw significant potential to scale the business and expand access to radiopharmaceutical therapies.

The transaction should therefore be understood as a transfer to an investor seeking to build a larger specialist healthcare business—not as the disappearance of BWXT Medical’s isotope-production capabilities.

What Is Included in the Business?

BWXT Medical develops, manufactures and supplies medical isotopes, radiochemicals, radiopharmaceutical products and related services.

Its commercial products and development pipeline have included isotopes and radiochemicals associated with diagnostic imaging and targeted radionuclide therapy, including germanium-68, strontium-82, actinium-225, lutetium-177 and lead-203. It has also been developing a technetium-99m generator and provides contract development, isotope sourcing, radiolabelling and manufacturing services.

The transaction also includes Kinectrics’ stable medical-isotope business.

Stable isotopes do not undergo radioactive decay, but some serve as target materials or precursors from which medically useful radioisotopes can be produced.

Kinectrics has expanded its production of highly enriched ytterbium-176, which can be irradiated to produce lutetium-177. In 2025, the company announced the commissioning of four electromagnetic isotope-separation units and said it intended to increase annual ytterbium-176 production capacity to more than 500 grams.

This stable-isotope capability is strategically important because expanding the clinical use of therapeutic radioisotopes requires reliable access not only to reactors or accelerators, but also to the specialised target materials placed inside those facilities.

The business therefore spans several parts of the nuclear-medicine value chain:

stable-isotope enrichment;
irradiation-target preparation;
radioisotope production;
radiochemical separation and purification;
radiopharmaceutical development;
quality control;
contract manufacturing;
regulatory support; and
distribution to pharmaceutical and healthcare customers.

That integrated capability helps explain why a specialised investor is prepared to attach a valuation of up to US$800 million to the transaction.

Nuclear Medicine Attracts Major Capital

The agreement reflects growing commercial interest in radiopharmaceuticals that combine radioactive isotopes with biological molecules capable of locating particular cells or tissues.

Diagnostic radiopharmaceuticals allow clinicians to observe biological processes using imaging technologies such as positron emission tomography and single-photon emission computed tomography.

Therapeutic radiopharmaceuticals carry radiation to specific disease sites, potentially delivering a concentrated dose to tumour cells while limiting exposure to surrounding healthy tissue.

Radiopharmaceuticals can therefore support diagnosis, patient selection, treatment and monitoring within a connected nuclear-medicine pathway.

Lutetium-177 is among the isotopes receiving increasing attention.

It can be combined with tumour-targeting molecules that direct the radioisotope towards diseased cells. The resulting radiopharmaceuticals are used in targeted radionuclide therapies for certain neuroendocrine tumours and prostate cancer.

The International Atomic Energy Agency has reported that the clinical success of radiolabelled peptides and enzyme inhibitors has contributed to increasing global demand for lutetium-177.

Other emerging therapeutic isotopes include actinium-225, which is being developed for targeted alpha therapies, while diagnostic isotopes such as germanium-68 support gallium-68 generators used in positron-emission imaging.

Investment is consequently moving beyond the production of traditional diagnostic isotopes towards specialised therapeutic products, stable-isotope enrichment, contract manufacturing and integrated radiopharmaceutical supply chains.

The Supply Chain Is Technically Demanding

Radiopharmaceuticals cannot be produced and distributed in the same way as most conventional medicines.

Some medical isotopes are created by irradiating targets inside research reactors or power reactors. Others are produced using particle accelerators such as cyclotrons.

The radioactive material must then be separated, purified, tested, incorporated into a pharmaceutical product and transported to the clinical facility under tightly controlled conditions.

The production chain may involve:

enriched stable-isotope production;
target fabrication;
reactor or accelerator irradiation;
radiochemical processing;
pharmaceutical formulation;
quality assurance and batch release;
licensed radioactive-material transport;
hospital preparation; and
administration to the patient.

Each stage requires specialised facilities, trained personnel, regulatory authorisations and radiation-protection arrangements.

The nuclear and pharmaceutical dimensions cannot be separated.

Medical-isotope production must comply with requirements relating to nuclear safety, radiation protection, radioactive-material transport and waste management, while radiopharmaceutical manufacture must also satisfy pharmaceutical standards for quality, sterility, purity, consistency, traceability and clinical use.

Radioactive Decay Creates a Logistics Challenge

Many medical isotopes have relatively short half-lives.

A half-life is the period required for half of a radioactive material’s activity to decay. As a radiopharmaceutical moves through the supply chain, part of its usable activity is continuously being lost.

Medical isotopes must therefore be delivered through carefully coordinated, time-sensitive distribution systems.

The IAEA notes that some radiopharmaceuticals must travel by the shortest and fastest possible route because delays can cause the product to lose effectiveness or become unusable.

Lutetium-177 has a half-life of approximately 6.7 days. This allows more time for transport than very short-lived positron-emission isotopes but still requires efficient production, processing, release and delivery. The OECD Nuclear Energy Agency has identified transport efficiency as an important part of the emerging lutetium-177 supply chain.

Other radiopharmaceuticals may have half-lives measured in hours or minutes.

Such products may need to be produced close to the hospital or within a regional distribution radius. An international supplier located thousands of kilometres away may not provide a practical or resilient source.

A Corporate Transaction Does Not Guarantee African Access

Nordic Capital’s acquisition could provide additional capital for manufacturing expansion, new isotope-development programmes and wider commercial distribution.

It may also support the construction of facilities, recruitment of specialised personnel and development of partnerships with pharmaceutical companies.

But the transaction does not automatically improve access in Africa.

Commercial expansion will generally follow markets where hospitals, insurers, health systems and pharmaceutical companies can sustain demand and meet the technical conditions required to use the products.

African countries without nuclear-medicine infrastructure may therefore remain outside the principal distribution networks even as global production expands.

Access depends on more than the availability of an isotope somewhere in the international market.

A country must be able to import, receive, test, prepare and administer the product safely. It must also have patients who can be appropriately diagnosed, selected and monitored.

The absence of any one component can prevent the complete treatment pathway from functioning.

What an Effective Nuclear-Medicine System Requires

Depending on the products and services being provided, a national or regional nuclear-medicine system may require:

research-reactor or cyclotron production capacity;
reliable access to imported isotopes;
irradiation targets and stable-isotope supplies;
radiochemical processing and hot-cell facilities;
pharmaceutical-grade production areas;
quality-control laboratories;
radiation-monitoring equipment;
licensed radioactive-material transport;
nuclear-medicine departments;
PET, SPECT or hybrid imaging systems;
trained radiochemists and radiopharmacists;
nuclear-medicine physicians;
medical physicists;
technologists and specialised nurses;
pharmaceutical and radiation regulators;
radioactive-waste arrangements; and
sustainable financing for patient treatment.

Not every country needs to possess every element.

A country may operate a cyclotron but import reactor-produced therapeutic isotopes. Another may rely entirely on regional suppliers while developing strong hospital, regulatory and transport capabilities.

The appropriate model should be determined by clinical demand, geography, disease burden, population distribution, available expertise and the economics of production.

Africa’s Workforce Constraint

Physical infrastructure alone is insufficient.

Radiopharmacists are responsible for preparing radiopharmaceuticals and ensuring their quality and safe use. They work at the intersection of pharmacy, nuclear science, radiation protection and clinical medicine.

The IAEA has identified shortages of qualified radiopharmacists as a major constraint on sustainable nuclear-medicine services in Africa.

Through regional training programmes in Morocco and South Africa, professionals from several African countries have received specialised radiopharmacy education. The African Association of Radiopharmacy was also established to strengthen professional cooperation and knowledge exchange.

Workforce development must extend beyond individual training courses.

Countries need recognised education programmes, clinical placements, professional certification, continuing education and career pathways capable of retaining specialised personnel.

A cyclotron or processing laboratory cannot operate sustainably if its trained staff leave and cannot be replaced.

Local Production Can Improve Resilience

Local production can reduce dependence on imported radiopharmaceuticals and provide greater control over scheduling, quality and continuity of supply.

Tunisia provides a recent example.

With IAEA support, Tunisia began national production of fluorine-18-labelled PSMA, a radiopharmaceutical used in the detection and staging of prostate cancer. Clinical use began in March 2026 after approval by the national medicines regulator.

The IAEA reported that domestic production reduced earlier constraints associated with import availability and logistics. The programme was supported by training for physicists, radiochemists, radiopharmacists and nuclear-medicine physicians, as well as the development of quality-assurance systems and a national radiopharmacy network.

The example shows that production equipment is only one part of the investment.

Sustainable domestic production also requires:

pharmaceutical regulation;
validated production protocols;
quality management;
workforce training;
hospital demand;
equipment maintenance;
reliable consumables;
transport arrangements; and
coordination between research institutions and health services.

Regional Hubs May Be More Practical

It may not be economically or technically appropriate for every African country to manufacture every medical isotope.

Some products require expensive reactors, accelerators, isotope-separation systems or radiochemical processing facilities. Production also needs sufficient and predictable demand to justify continuing operation.

A regional hub model may therefore be more practical.

Under such a model, different countries or institutions could specialise in particular parts of the value chain.

One country might operate a research reactor capable of irradiation. Another could provide cyclotron-produced diagnostic isotopes. A regional processing centre could perform radiochemical separation and pharmaceutical manufacturing, while a network of hospitals provides clinical services.

A possible regional system could connect:

research reactors;
medical cyclotrons;
stable-isotope suppliers;
target-fabrication facilities;
processing laboratories;
quality-control centres;
specialised transport providers;
teaching hospitals; and
regional workforce-development institutions.

This would allow participating countries to share infrastructure while avoiding unnecessary duplication.

However, regional production will succeed only if customs, transport, pharmaceutical regulation, radiation protection and product-release requirements are coordinated.

An isotope with a short half-life cannot remain at an airport or border post while authorities debate documentation.

The Role of African Research Reactors

Research reactors can support medical-isotope production by providing neutron irradiation for suitable targets.

The IAEA identifies radioisotope production as one of the major applications of research reactors, alongside education, training, materials research, neutron activation analysis and industrial services.

Africa already possesses research-reactor institutions and associated nuclear-science centres. These facilities vary considerably in power, age, operational status, technical configuration and utilisation.

Not every research reactor is capable of producing isotopes at commercial scale.

A reactor may lack:

sufficient neutron flux;
appropriate irradiation positions;
target-handling systems;
hot cells;
radiochemical-processing facilities;
pharmaceutical-grade laboratories;
quality-control systems;
trained production personnel; or
reliable operating schedules.

The policy objective should therefore not be to label every African research reactor as a future isotope factory.

Each facility should undergo a realistic technical and economic assessment to determine which isotopes it could produce, at what scale, under what regulatory conditions and for which regional market.

Improve Utilisation Before Building New Facilities

Some countries may be able to expand isotope-related services by improving the utilisation of existing reactors and nuclear-science centres.

Possible investments include:

refurbishment of irradiation systems;
installation of modern hot cells;
improved ventilation and containment;
radiochemical-processing equipment;
clean-room and pharmaceutical-production areas;
analytical and quality-control laboratories;
radioactive-waste systems;
packaging and transport capabilities;
digital production management; and
workforce training.

These upgrades may be less costly than constructing completely new research reactors.

However, governments should avoid forcing facilities into commercial production where the necessary demand, technical capacity or safety infrastructure is absent.

Research reactors must continue to meet their primary safety and security obligations. Commercial pressure to produce isotopes should never override safe operation, maintenance or regulatory compliance.

Cyclotrons Are Equally Important

Research reactors are not the only production option.

Cyclotrons produce many isotopes required for positron-emission tomography and other medical applications. They can often be located at hospitals, universities or regional medical centres.

The IAEA notes that radiopharmaceutical isotopes may be produced either through irradiation in research reactors or through particle accelerators, depending on the isotope required.

Cyclotron development may offer particular advantages for shorter-lived isotopes that cannot be transported over long distances.

But cyclotron projects still require:

stable electricity;
specialised building infrastructure;
radiation shielding;
target systems;
radiochemistry laboratories;
maintenance contracts;
trained operators;
quality-control systems; and
sufficient clinical demand.

A cyclotron without a functioning radiopharmacy and hospital distribution network may become an expensive underutilised asset.

Regulation Must Cover Both Nuclear and Pharmaceutical Risks

Radiopharmaceutical regulation crosses several institutional mandates.

The nuclear or radiation regulator may supervise radioactive-material possession, worker exposure, facility safety, waste management and transport.

The medicines regulator is responsible for pharmaceutical quality, safety and efficacy.

Health ministries, customs authorities, transport agencies and professional licensing bodies may also have relevant responsibilities.

Poor coordination can delay product approval or create regulatory gaps.

Countries seeking to expand nuclear medicine should establish clear arrangements for:

facility licensing;
pharmaceutical manufacturing authorisation;
product registration;
batch release;
radiation protection;
occupational exposure;
patient dosimetry;
transport authorisation;
import and export;
radioactive-waste management;
incident reporting; and
post-market surveillance.

Regional harmonisation could help suppliers serve several countries without repeating completely different approval procedures.

But harmonisation should not weaken patient protection or pharmaceutical quality.

Public Investment Still Matters

The BWXT transaction demonstrates that private investors see significant commercial potential in nuclear medicine.

Private capital can help expand production, develop new radiopharmaceuticals and build international distribution networks.

But many essential parts of the African nuclear-medicine ecosystem may not generate immediate commercial returns.

Governments and development partners may still need to finance:

university programmes;
regulatory capacity;
public hospitals;
research laboratories;
professional training;
quality-assurance systems;
transport infrastructure;
patient subsidies; and
regional coordination.

Without this public foundation, private suppliers may find that African markets are technically unprepared or financially inaccessible.

The policy challenge is therefore to combine private-sector production and innovation with public investment in health-system readiness.

Avoid Unsustainable National Prestige Projects

The commercial growth of nuclear medicine may encourage governments to announce national isotope-production facilities as symbols of technological progress.

Such projects should be approached cautiously.

A facility should not be built merely because another country operates one.

Before investing, governments should determine:

which isotopes are required;
the present and projected number of patients;
whether regional supply is available;
whether the product can be transported within its usable lifetime;
whether local production is economically justified;
whether trained personnel are available;
whether the regulator is ready;
whether hospitals can use the products;
how maintenance and consumables will be financed; and
how waste will be managed.

A production facility that operates intermittently or lacks clinical demand will not improve access.

Africa Should Participate Across the Value Chain

The transaction also raises a broader industrial-policy question.

Africa should not participate in the radiopharmaceutical economy only as an end-user importing expensive finished products.

Selected African institutions could contribute to:

isotope and radiopharmaceutical research;
clinical trials;
target development;
radiochemistry;
pharmaceutical formulation;
dosimetry;
software and imaging analysis;
equipment maintenance;
quality-control services;
workforce education; and
regional distribution.

Countries with established nuclear centres, research reactors, cyclotrons and pharmaceutical industries could develop specialised areas of comparative advantage.

A continent-wide strategy does not require every country to perform every function.

It requires connected centres of excellence capable of supporting one another.

A Possible African Nuclear-Medicine Strategy

African governments, regional institutions and professional bodies could respond to the expanding radiopharmaceutical market through a coordinated programme built around five priorities.

1. Map existing capacity

A regional database should identify research reactors, cyclotrons, radiopharmacies, hot cells, quality-control laboratories, PET and SPECT systems, specialised hospitals and trained professionals.

2. Identify priority isotopes

Countries should determine which diagnostic and therapeutic isotopes are most relevant to their cancer and cardiovascular disease burdens.

3. Establish regional production corridors

Production facilities should be connected to predictable transport routes and clinical centres capable of using the products before excessive radioactive decay occurs.

4. Strengthen regulation and quality assurance

Nuclear regulators, medicines authorities and health ministries should develop coordinated licensing and product-approval procedures.

5. Invest in workforce development

Regional radiopharmacy, nuclear-medicine, medical-physics and radiochemistry programmes should support both national services and regional centres of excellence.

The African Regional Cooperative Agreement for Research, Development and Training Related to Nuclear Science and Technology could provide a framework for elements of this cooperation, alongside the IAEA, the African Union, regional economic communities and professional associations.

Investment Is Growing, but Access Is Not Automatic

The proposed sale of BWXT Medical and Kinectrics’ stable medical-isotope business demonstrates that nuclear medicine is becoming a substantial commercial market.

Private investors increasingly recognise the value of isotope enrichment, reactor irradiation, radiochemical processing, pharmaceutical manufacturing and targeted radionuclide therapies.

That growth could expand the availability of diagnostic and therapeutic products internationally.

But corporate investment alone will not overcome Africa’s access constraints.

Patients cannot benefit from an isotope that cannot be imported, transported, tested, prepared or administered safely.

African governments must therefore invest in the complete nuclear-medicine ecosystem—from research and production to regulation, transport, hospitals and specialised personnel.

The continent does not need every country to produce every isotope.

It needs a connected regional system that gives patients reliable access to the right product, at the right hospital, at the right time.

The BWXT transaction shows that nuclear medicine has become an important commercial industry.

Africa’s challenge is to ensure that it also becomes an accessible public-health service.

BWXT Agrees US$800 Million Medical-Isotope Sale as Radiopharmaceutical Market Expands